Rhythm Pharmaceuticals (RYTM) Stock Price, News & Analysis

Company Overview

Rhythm Pharmaceuticals, Inc. is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1. Rhythm has advanced multiple Phase 3 clinical trials for setmelanotide and is pursuing regulatory approvals in both the United States and the European Union. In addition to its lead program, the company is exploring opportunities in related rare obesity indications and branching into other metabolic disorders tied to melanocortin pathway dysfunction.

Founded in 2013 and headquartered in Boston, Massachusetts, Rhythm Pharmaceuticals is led by a management team with extensive experience in drug development, regulatory strategy and commercialization of therapies for rare diseases. The company maintains a robust intellectual property portfolio around its peptide technology and collaborates with academic institutions and patient advocacy groups to advance understanding of rare genetic forms of obesity. Rhythm’s work underscores a commitment to precision medicine approaches that address the root causes of metabolic disorders.

Key Stats

• Today's Range: $96.74 to $102.79
• 50-Day Range: $84.66 to $104.57
• 52-Week Range: $45.90 to $106.52
• Volume: 450,431 shs
• Average Volume: 659,148 shs
• Market Capitalization: $6.61 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $106.64
• Consensus Rating: Buy

Rhythm Pharmaceuticals Stock Analysis - MarketRank™

Rhythm Pharmaceuticals scored higher than 71% of companies evaluated by MarketBeat, and ranked 304th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.1 / 5
• Analyst Rating: Buy

Consensus Rating

Rhythm Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.06, and is based on 15 buy ratings, no hold ratings, and no sell ratings.

Upside/Downside

The consensus price target for Rhythm Pharmaceuticals is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Rhythm Pharmaceuticals has been the subject of 14 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Rhythm Pharmaceuticals are expected to grow in the coming year, from ($4.32) to ($2.58) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Rhythm Pharmaceuticals is -33.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Rhythm Pharmaceuticals is -33.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Rhythm Pharmaceuticals has a P/B Ratio of 284.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.86% of the outstanding shares of Rhythm Pharmaceuticals have been sold short.

Short Interest Ratio / Days to Cover

Rhythm Pharmaceuticals has a short interest ratio ("days to cover") of 7.2.

Change versus previous month

Short interest in Rhythm Pharmaceuticals has recently increased by 5.03%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Rhythm Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Rhythm Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.3 / 5
• Environmental Score: -1.80

Percentage of Shares Shorted

7.86% of the outstanding shares of Rhythm Pharmaceuticals have been sold short.

Short Interest Ratio / Days to Cover

Rhythm Pharmaceuticals has a short interest ratio ("days to cover") of 7.2.

Change versus previous month

Short interest in Rhythm Pharmaceuticals has recently increased by 5.03%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 0.75

News Sentiment

Rhythm Pharmaceuticals has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Rhythm Pharmaceuticals this week, compared to 9 articles on an average week.

Search Interest

3 people have searched for RYTM on MarketBeat in the last 30 days.

MarketBeat Follows

2 people have added Rhythm Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Rhythm Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,274,593.00 in company stock.

Percentage Held by Insiders

Only 6.10% of the stock of Rhythm Pharmaceuticals is held by insiders.

RYTM Stock Analysis - Frequently Asked Questions

How have RYTM shares performed this year?

Rhythm Pharmaceuticals' stock was trading at $55.98 on January 1st, 2025. Since then, RYTM shares have increased by 77.6% and is now trading at $99.4450.

How were Rhythm Pharmaceuticals' earnings last quarter?

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) issued its quarterly earnings results on Tuesday, August, 5th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by $0.09. The company's quarterly revenue was up 66.8% on a year-over-year basis.
Read the conference call transcript.

When did Rhythm Pharmaceuticals IPO?

Rhythm Pharmaceuticals (RYTM) raised $100 million in an IPO on Thursday, October 5th 2017. The company issued 6,700,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen served as the underwriters for the IPO and Needham was co-manager.

How do I buy shares of Rhythm Pharmaceuticals?

Shares of RYTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Rhythm Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Rhythm Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Netflix (NFLX), Tesla (TSLA) and Palo Alto Networks (PANW).

Company Calendar

• Last Earnings: 8/05/2025
• Today: 10/03/2025
• Next Earnings (Estimated): 11/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:RYTM
• CIK: 1649904
• Web: www.rhythmtx.com
• Phone: (857) 264-4280
• Fax: 857-264-4299
• Employees: 140
• Year Founded: 2008

Price Target and Rating

• Average Price Target for Rhythm Pharmaceuticals: $106.64
• High Price Target: $142.00
• Low Price Target: $65.00
• Potential Upside/Downside: +9.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.06
• Research Coverage: 16 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$260.60 million
• Net Margins: -117.13%
• Pretax Margin: -117.17%
• Return on Equity: -1,831.43%
• Return on Assets: -48.33%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.79
• Quick Ratio: 2.64

Sales & Book Value

• Annual Sales: $130.13 million
• Price / Sales: 49.63
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.35 per share
• Price / Book: 277.80

Miscellaneous

• Outstanding Shares: 66,420,000
• Free Float: 62,368,000
• Market Cap: $6.46 billion
• Optionable: Optionable
• Beta: 2.12